Weighing the gold in the gold standard: Challenges in HIV prevention research

AIDS

Volumn 24, Issue 5, 2010, Pages 621-635

  Padian, Nancy S ^a,b   McCoy, Sandra I ^b   Balkus, Jennifer E ^c   Wasserheit, Judith N ^c  

^a University of Southern California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adherence; Behavior circumcision; Control group HIV infection; Microbicide; PrEP prevention; Sexually transmitted infections statistical power; Vaccines

Indexed keywords

ACICLOVIR; ALVAC HIV VACCINE; ANTIRETROVIRUS AGENT; AZITHROMYCIN; CIPROFLOXACIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; METRONIDAZOLE; MICROBICIDE; NONOXINOL 9; TENOFOVIR; UNCLASSIFIED DRUG; VACCINE; VIRUS VACCINE;

BEHAVIOR THERAPY; BIOMEDICINE; CIRCUMCISION; CLINICAL EVALUATION; CLINICAL RESEARCH; CLINICAL TRIAL; DILUTION; DRUG EFFICACY; FINANCE; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INFECTION PREVENTION; INFORMATION PROCESSING; INTERVENTION STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS LOAD;

HIV INFECTIONS; HUMANS; PROGRAM EVALUATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 77949363499     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328337798a     Document Type: Review

References (86)

1. Wasserheit JN. The STD-HIV connection from research to action: are we lost in translation? In: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles California; 2007.
2. Padian NS. Biomedical HIV prevention: current status, challenges, and future directions. 4th Annual International AIDS Society. Sydney; 2007.
3. Wasserheit JN. STI/HIV prevention research: the agony, the ecstasy, & the future. 18th International Society for Sexually Transmitted Disease Research. London; 2009.
4. Lay PD. AIDS remains an exceptional issue. BMJ Rapid Response 2008. http://www.bmj.com/cgi/eletters/336/7652/1072
5. UNAIDS. Report on the Global AIDS Epidemic. Geneva; 2008.
6. Institute of Medicine (IOM). Methodological Challenges in Bio-medical HIV Prevention Trials. Washington, D.C.: The National Academies Press; 2008.
7. Padian NS, Buve A, Balkus J, Serwadda D, Cates W Jr. Biome-dical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet 2008; 372:585-599.
8. Weiss HA, Wasserheit JN, Barnabas RV, Hayes RJ, Abu-Raddad LJ. Persisting with prevention: the importance of adherence for HIV prevention. Emerg Themes Epidemiol 2008; 5:8.
9. Potts M, Halperin DT, Kirby D, Swidler A, Marseille E, Klausner JD, et al. Public health. Reassessing HIV prevention. Science 2008; 320:749-750.
10. Grant RM, Hamer D, Hope T, Johnston R, Lange J, Lederman MM, et al. Whither or wither microbicides? Science 2008; 321:532-534.
11. Lagakos SW, Gable AR. Challenges to HIV prevention: seeking effective measures in the absence of a vaccine. N Engl J Med 2008; 358:1543-1545.
12. GrosskurthH, GrayR, Hayes R, Mabey D,WawerM.Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials. Lancet 2000; 355:1981-1987.
13. The Cochrane Collaboration. Cochrane Handbook for systematic reviews of interventions version 5.0.1 [updated September 2008]. In: Higgins JPT, Green S, editors 2008.
14. Kamb ML, Fishbein M, Douglas JM Jr, Rhodes F, Rogers J, Bolan G, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA 1998; 280:1161-1167.
15. Hobfoll SE, Jackson AP, Lavin J, Johnson RJ, Schroder KE. Effects and generalizability of communally oriented HIV-AIDS prevention versus general health promotion groups for single, inner-city women in urban clinics. J Consult Clin Psychol 2002; 70:950-960.
16. Branson BM, Peterman TA, Cannon RO, Ransom R, Zaidi AA. Group counseling to prevent sexually transmitted disease and HIV: a randomized controlled trial. Sex Transm Dis 1998; 25:553-560.
17. Baker SA, Beadnell B, Stoner S, Morrison DM, Gordon J, Collier C, et al. Skills training versus health education to prevent STDs/ HIV in heterosexual women: a randomized controlled trial utilizing biological outcomes. AIDS Educ Prev 2003; 15:1-14.
18. Pequagnat W; Group NCHSPT. Results of the RCT to test the community popular opinion leader (C-POL) intervention in five countries [abstract no. LBPE1166]. AIDS 2008-XVII international AIDS Conference.
19. Kamali A, Quigley M, Nakiyingi J, Kinsman J, Kengeya-Kayondo J, Gopal R, et al. Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet 2003; 361:645-652.
20. Karim SA, Coletti A, Richardson B, Ramjee G, Hoffman I, Chirenje M, et al. Safety and effectiveness of vaginal micro-bicides BufferGel and 0.5% PRO 2000/5 gel for the prevention of HIV infection in women: results of the HPTN 035 trial. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada; 2009.
21. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1998.
22. Cohen MS. Preventing sexual transmission of HIV. Clin Infect Dis 2007; 45 (Suppl 4):S287-S292.
23. Vermund SH, Allen KL, Karim QA. HIV-prevention science at a crossroads: advances in reducing sexual risk. Curr Opin HIV AIDS 2009; 4:266-273.
24. Gray RH. Methodologies for evaluating HIV prevention intervention (populations and epidemiologic settings). Curr Opin HIV AIDS 2009; 4:274-278.
25. Medical Research Council. Microbicide gel safe but not effective in preventing HIV infection. Press release. Durban; 14 December 2009.
26. Cowan FM, Pascoe SJS, Langhaug LF, Dirawo J, Mavhu W, Chidiya S, et al. The Regai Dzive Shiri project: results of a cluster randomized trial of a multi-component HIV prevention intervention for rural Zimbabwean adolescents. 18th International Society for Sexually Transmitted Disease Research. London; 2009.
27. Gray GE, Allen MA, Bekker L, Churchyard G, Mlisana K, Nchabeleng M, et al. Results from the Phambili (HVTN 503) study: a multicenter phase IIB test-of-concept study of the MRKad5 HIV-1Gag/Pol/Nef vaccine in South Africa. AIDS Vaccine. Cape Town; 2008.
28. Celum C, Wald A, Lingappa J, Magaret A, Wang R, Mugu N, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362: 427-439.
29. Koblin B, Chesney M, Coates T. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet 2004; 364:41-50.
30. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Mor-etlwe S, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:2109-2119.
31. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glyco-protein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-665.
32. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881-1893.
33. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008; 359:463-472.
34. Van Damme L, Ramjee G, AlaryM, Vuylsteke B,Chandeying V, Rees H, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002; 360:971-977.
35. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009. http:// content.nejm.org/cgi/content/full/361/23/ 2209.
36. Ross DA, Changalucha J, Obasi AI, Todd J, Plummer ML, Cleophas-Mazige B, et al. Biological and behavioural impact of an adolescent sexual health intervention in Tanzania: a community-randomized trial. AIDS 2007; 21:1943-1955.
37. Corbett EL, Makamure B, Cheung YB, Dauya E, Matambo R, Bandason T, et al. HIV incidence during a cluster-randomized trial of two strategies providing voluntary counselling and testing at the workplace, Zimbabwe. AIDS 2007; 21:483-489.
38. Jewkes R, Nduna M, Levin J, Jama N, Dunkle K, Puren A, Duvvury N. Impact of stepping stones on incidence of HIV and HSV-2 and sexual behaviour in rural South Africa: cluster randomised controlled trial. BMJ 2008; 337:a506.
39. Pronyk PM, Hargreaves JR, Kim JC, Morison LA, Phetla G, Watts C, et al. Effect of a structural intervention for the prevention of intimate-partner violence and HIV in rural South Africa: a cluster randomised trial. Lancet 2006; 368:1973-1983.
40. Grosskurth H, Mosha F, Todd J, Mwijarubi E, Klokke A, Senkoro K, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995; 346:530-536.
41. Wawer MJ, Sewankambo NK, Serwadda D, Quinn TC, Paxton LA, Kiwanuka N, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet 1999; 353:525-535.
42. GregsonS,AdamsonS,PapayaS,MundondoJ,Nyamukapa CA, Mason PR, et al. Impact and process evaluation of integrated community and clinic-based HIV-1 control: a cluster-randomised trial in eastern Zimbabwe. PLoS Med 2007; 4:e102.
43. Wawer MJ, Makumbi F, Kigozi G, Serwadda D, Watya S, Nalugoda F, et al. Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet 2009; 374:229-237.
44. Kreiss J, Ngugi E, Holmes K, Ndinya-Achola J, Waiyaki P, Roberts PL, et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 1992; 268:477-482.
45. Roddy RE, ZekengL,Ryan KA, TamoufeU, Weir SS, Wong EL. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998; 339:504-510.
46. Richardson BA, Lavreys L, Martin HL Jr, Stevens CE, Ngugi E, Mandaliya K, et al. Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex Transm Dis 2001; 28:394-400.
47. Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M, Boakye AY, et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One 2007; 2:e1312.
48. Halpern V, Ogunsola F, Obunge O, Wang CH, Onyejepu N, Oduyebo O, et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One 2008; 3:e3784.
49. Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008; 3:e1474.
50. Peterson L, Taylor D, Roddy R, Belai G, Phillips P, Nanda K, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2007; 2:e27.
51. Ghys PD, Diallo MO, Ettiegne-Traore V, Satten GA, Anoma CK, Maurice C, et al. Effect of interventions to control sexually transmitted disease on the incidence of HIV infection in female sex workers. AIDS 2001; 15:1421-1431.
52. Kaul R, Kimani J, Nagelkerke NJ, Fonck K, Ngugi EN, Keli F, et al. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA 2004; 291:2555-2562.
53. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Bais-ley K, Mugeye K, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358:1560-1571.
54. Padian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, Blanchard K, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet 2007; 370:251-261.
55. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1977-1987.
56. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalu-goda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369:657-666.
57. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369:643-656.
58. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Med 2005; 2:e298.
59. Patterson TL, Mausbach B, Lozada R, Staines-Orozco H, Semple SJ, Fraga-Vallejo M, et al. Efficacy of a brief behavioral intervention to promote condom use among female sex workers in Tijuana and Ciudad Juarez, Mexico. Am J Public Health 2008; 98:2051-2057.
60. Gray G, Allen M, Churchyard G, Bekker L, Nchabeleng M, Mlisana K, et al. A multicenter double-blind randomized placebo-controlled phase IIB test-of-concept study to evaluate the safety and efficacy of a 3-dose regimen of the Clade B-based Merck Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine in HIV-1-uninfected adults in South Africa. AIDS Vaccine. Paris; 2009.
61. Corey L, McElrath MJ, Kublin JG. Poststep modifications for research on HIV vaccines. AIDS 2009; 23:3-8.
62. Long-term evaluation of the MEMA kwa Vijana Adolescent Sexual Health ProgrammeinRural Mwanza, Tanzania:aRando-mised controlled trial. Technical Briefing Paper: No. 7; 2008.
63. Cowan FM, Pascoe SJ, Langhaug LF, Dirawo J, Chidiya S, Jaffar S, et al. The Regai Dzive Shiri project: a cluster randomised controlled trial to determine the effectiveness of a multicom-ponent community-based HIV prevention intervention for rural youth in Zimbabwe-study design and baseline results. Trop Med Int Health 2008; 13:1235-1244.
64. Patterson TL, Orozovich P, Semple SJ, Orozco HSS, Fraga M, Amaro H, et al. A sexual risk reduction intervention for female sex workers in Mexico: design and baseline characteristics. J HIV/AIDS Soc Services 2006; 5:115-137.
65. U.S. Military HIV Research Program. RV144 phase III HIV vaccine trial press release. Rockville, MD 2009.
66. Hargreaves JR, Bonell CP, Morison LA, Kim JC, Phetla G, Porter JD, et al. Explaining continued high HIV prevalence in South Africa: socioeconomic factors, HIV incidence and sexual behaviour change among a rural cohort, 2001-2004. AIDS 2007; 21 (Suppl 7):S39-S48.
67. Quigley MA, Kamali A, Kinsman J, Kamulegeya I, Nakiyingi Miiro J, Kiwuwa S, et al. The impact of attending a behavioural intervention on HIV incidence in Masaka, Uganda. AIDS (Lond) 2004; 18:2055-2063.
68. DelanyS,MlabaN,ClaytonT,AkpomiemieG,CapovillaA,Legoff J, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 2009; 23:461-469.
69. Zhu J, Hladik F, Woodward A, Klock A, Peng T, Johnston C, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009. http://www.nature.com/nm/journal/v15/ n8/abs/nm.2006.html.
70. Buchbinder S. Clinical outcomes from the STEP study. AIDS Vaccine. Paris 2009
71. UNAIDS. Evaluation of the 100% Condom Programme in Thailand. UNAIDS case study. Geneva; 2000.
72. Green EC, Halperin DT, Nantulya V, Hogle JA. Uganda's HIV prevention success: the role of sexual behavior change and the national response. AIDS Behav 2006; 10:335-346; discussion 347-350.
73. Potts M. Thinking about vaginal microbicide testing. Am J Public Health 2000; 90:188-190.
74. van de Wijgert J, Elias C, Ellertson C, McGrory E, Blanchard K, Friedland B, et al. Condom promotion in microbicide trials. Am J Public Health 2000; 90:1153-1154; author reply 1156.
75. Lurie P, Wolfe SM. Ethics require the inclusion of condoms and counseling in anti-HIV microbicide trials. Am J Public Health 2000; 90:1154-1155; author reply 1156.
76. de Zoysa I, Elias CJ, Bentley ME. Microbicide research and 'the investigator's dilemma'. Am J Public Health 2000; 90:1155; author reply 1156.
77. Brown CA, Lilford RJ. The stepped wedge trial design: a systematic review. BMC Med Res Methodol 2006; 6:54.
78. Baeten JM, Richardson BA, Martin HL Jr, Nyange PM, Lavreys L, Ngugi EN, et al. Trends in HIV-1 incidence in a cohort of prostitutes in Kenya: implications for HIV-1 vaccine efficacy trials. J Acquir Immune Defic Syndr 2000; 24:458-464.
79. Halpern V, Obunge O, Ogunsola F, Otusanya S, Umo-Otong J, Wang CH, Mehta N. Interim data monitoring to enroll higher-risk participants in HIV prevention trials. BMC Med Res Meth-odol 2009; 9:44.
80. Kaul R, Kimani J, Nagelkerke NJ, Fonck K, Keli F, MacDonald KS, et al. Reduced HIV risk-taking and low HIV incidence after enrollment and risk-reduction counseling in a sexually transmitted disease prevention trial in Nairobi, Kenya. J Acquir Immune Defic Syndr 2002; 30:69-72.
81. Centers for Disease Control and Prevention. Status of the Botswana TDF2 Study of Pre-Exposure Prophylaxis for HIV Prevention. CDC Fact Sheet. Atlanta, Georgia; December 2009.
82. Merson M, Padian N, Coates TJ, Gupta GR, Bertozzi SM, Piot P, et al. Combination HIV prevention. Lancet 2008; 372:1805-1806.
83. PiotP, Bartos M, LarsonH,ZewdieD, ManeP. Coming to terms with complexity: a call to action for HIV prevention. Lancet 2008; 372:845-859.
84. Manhart LE, Holmes KK. Randomized controlled trials of individual-level, population-level, and multilevel interventions for preventing sexually transmitted infections: what has worked? J Infect Dis 2005; 191 (Suppl 1):S7-24
85. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Baltimore: Williams & Wilkins; 1996.
86. Hill AB. The environment and disease: association or causation? Proc Royal Soc Med 1965; 58:295-300.